Massimo Calafiore Sells 9,797 Shares of Orthofix Medical (NASDAQ:OFIX) Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore sold 9,797 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $15.21, for a total value of $149,012.37. Following the sale, the chief executive officer directly owned 217,237 shares of the company’s stock, valued at approximately $3,304,174.77. The trade was a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Massimo Calafiore also recently made the following trade(s):

• On Friday, January 9th, Massimo Calafiore sold 9,600 shares of Orthofix Medical stock. The stock was sold at an average price of $15.82, for a total value of $151,872.00.

Orthofix Medical Stock Down 2.9%

Shares of NASDAQ:OFIX traded down $0.44 during midday trading on Tuesday, hitting $14.81. The stock had a trading volume of 187,589 shares, compared to its average volume of 227,586. The company has a market cap of $586.48 million, a P/E ratio of -4.89 and a beta of 0.79. Orthofix Medical Inc. has a 12 month low of $10.24 and a 12 month high of $20.48. The business’s 50-day simple moving average is $15.39 and its 200-day simple moving average is $14.23. The company has a quick ratio of 1.38, a current ratio of 2.47 and a debt-to-equity ratio of 0.39.

Hedge Funds Weigh In On Orthofix Medical

Several institutional investors have recently bought and sold shares of OFIX. AYAL Capital Advisors Ltd grew its stake in Orthofix Medical by 74.7% during the second quarter. AYAL Capital Advisors Ltd now owns 943,203 shares of the medical device company’s stock valued at $10,517,000 after acquiring an additional 403,433 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Orthofix Medical by 515.6% in the 2nd quarter. Squarepoint Ops LLC now owns 117,666 shares of the medical device company’s stock valued at $1,312,000 after purchasing an additional 98,552 shares during the period. Gradient Capital Advisors LLC purchased a new position in shares of Orthofix Medical during the 2nd quarter valued at $223,000. Engine Capital Management LP grew its position in shares of Orthofix Medical by 13.6% during the 2nd quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock valued at $47,406,000 after purchasing an additional 510,281 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Orthofix Medical in the second quarter worth $147,000. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Analyst Ratings Changes

OFIX has been the topic of several recent research reports. Barrington Research raised their target price on shares of Orthofix Medical from $17.00 to $18.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Stifel Nicolaus initiated coverage on shares of Orthofix Medical in a research report on Tuesday, October 28th. They set a “buy” rating and a $22.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.50.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.